FDA Approved: ZALTRAP — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for Zaltrap (ziv-aflibercept) from Sanofi-Aventis U.S. LLC, adding/expanding its marketed indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

SUPPL AP for ZALTRAP (ZIV-AFLIBERCEPT)